Stockscreener 앱 받기
162.03
3.99%
6.21
시간 외 거래:
162.03
Astrazeneca Plc 주식(AZN)의 최신 뉴스
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? - Zacks Investment Research
AstraZeneca reports HICKORY Phase III results for AstraZeneca stock - ad-hoc-news.de
AstraZeneca Summit Deal: What Does Completion Unlock? - Kalkine Media
AstraZeneca PLCAmerican Depositary Shares (NYSE:AZN) Stock Quote - FinancialContent
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint - Yahoo Finance
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual MeetingSlideshow (NYSE:AZN) 2026-10-12 - Seeking Alpha
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi - Proactive financial news
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal - Benzinga
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response - Clinical Trials Arena
Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab - TradingView
AstraZeneca PLC (AZN) stock price, news, quote and history - Yahoo Finance Australia
ASTRAZENECA PLC CEDEAR EA RE 0. (AZND.BA) Q1 FY2026 earnings call transcript - Yahoo Finance
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth? - Yahoo Finance
AstraZeneca falls Thursday, underperforms market - MarketWatch
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
Form 4 ASTRAZENECA PLC For: 8 October By Investing.com - Investing.com UK
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square - Yahoo Finance
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results - Proactive financial news
AstraZeneca PLC : Buy rating from Berenberg - www.marketscreener.com
US bank expects AstraZeneca to beat third-quarter forecasts as path clears to key lung cancer data - Proactive Investors
AstraZeneca PLC : Jefferies gives a Buy rating - www.marketscreener.com
AstraZeneca PLC : Bernstein reaffirms its Buy rating - www.marketscreener.com
AstraZeneca Takes Drug-Pricing Law Challenge To 4th Circ. - Law360
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus - TipRanks
AstraZeneca advances Tuesday, outperforms market - MarketWatch
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Citi raises AstraZeneca target to £186 as tozorakimab prospects improve - Proactive financial news
AstraZeneca opens new R&D centre in Cambridge, US - Pharmaceutical Technology
AstraZeneca Invests Over $1bn in Massachusetts - marketscreener.com
AstraZeneca Launches Research, Development Center in US - marketscreener.com
‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans - The Business Journals
AstraZeneca CEO Soriot says drugmaker can grow without big acquisition - Seeking Alpha
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment - CNBC
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce - marketscreener.com
AstraZeneca to invest over $1B in Massachusetts ops - Breakingthenews.net
A Massachusetts investment will expand AstraZeneca’s state workforce by over 50% in coming years. - Stock Titan
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts - Financial Times
AstraZeneca PLC (ZEG.DE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Summit Therapeutics Closes $2 Billion AstraZeneca Investment - grafa.com
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - TradingView
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - Zacks Investment Research
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting - Zacks Investment Research
AstraZeneca completes USD2 billion Summit investment - marketscreener.com
Cancer-drug partnerships accompany AstraZeneca (AZN)'s completed investment in Summit. - Stock Titan
AstraZeneca Finalizes $2 Billion Investment in Summit Therapeutics - marketscreener.com
3.27%
자본화:
|
볼륨(24시간):